임상 검사 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Clinical Laboratory Tests Market was valued at USD 125.5 billion in 2024 and is estimated to grow at a CAGR of 9.1% to reach USD 298.4 billion by 2034, fueled by rising chronic disease cases, the aging global population, and the increasing reliance on diagnostic testing for early detection and treatment monitoring. Laboratory testing helps in medical decision-making, with most diagnostic workflows depending on tools like reagents, analyzers, and specimen collection systems. Aging populations, especially in developed regions, contribute significantly to testing demand due to their susceptibility to chronic illnesses such as heart disease, cancer, and diabetes.

Adoption of AI and automation has improved test turnaround time and accuracy. Modern laboratories now integrate machine learning and robotics into workflows to reduce manual errors, boost operational efficiency, and manage rising sample volumes. The move toward personalized medicine pushes demand for precise diagnostics and multi-analyte tests. Clinical testing has become a regular part of preventive healthcare strategies worldwide, and regular health screenings are becoming increasingly common, even in emerging economies.

In 2024, HbA1c tests accounted for the largest market share, contributing 13.9% of total revenue. These tests are essential for monitoring long-term blood glucose control, particularly in patients with diabetes. Technological improvements such as portable analyzers and automated systems have made HbA1c testing more accessible and efficient. Growing public awareness around early diagnosis and disease management has also pushed the frequency of these tests. With diabetes cases rising globally, demand for regular monitoring continues to surge, driving sustained growth for this segment.

The central laboratories segment held the largest share in 2024, accounting for USD 47.2 billion, supported by high-throughput diagnostic capabilities, well-established infrastructure, and strong integration with hospitals and research institutions. These labs are equipped to handle complex tests, including genetic and molecular diagnostics, and maintain consistency in results across wide geographical networks. Their cost-effective solutions and reliability make them the preferred option for large-scale testing needs.

U.S. Clinical Laboratory Tests Market was valued at USD 50.8 billion in 2024 and is projected to reach USD 119.3 billion by 2034, driven by multiple structural and technological factors. High per capita healthcare spending enables widespread integration of cutting-edge diagnostic technologies across hospitals, clinics, and research labs. The rising incidence of chronic illnesses, infectious diseases, and age-related health conditions further amplifies the need for timely and accurate laboratory testing. Increasing reliance on molecular diagnostics, personalized medicine, and early disease detection tools is reshaping clinical workflows nationwide.

Key players in this space include Siemens Healthineers, bioMerieux, Agilent Technologies, Illumina, Thermo Fisher Scientific, Abbott Laboratories, Hologic, Bio-Rad Laboratories, QIAGEN, Danaher, and PerkinElmer. To strengthen market presence, companies are focusing on partnerships with healthcare providers, expanding laboratory automation, and investing in AI-based platforms. They also aim to diversify test menus, acquire smaller diagnostic firms, and increase their global distribution networks. Regulatory compliance, product innovation, and cost-effective solutions remain critical to staying competitive in the evolving diagnostic landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and infectious diseases
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Shortage of skilled laboratory personnel
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (cost of manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (cost to consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Complete blood count
• 5.3 HbA1c
• 5.4 Metabolic panel
• 5.5 Liver panel
• 5.6 Renal panel
• 5.7 Lipid panel
• 5.8 Cardiovascular panel
• 5.9 Other test types

Chapter 6 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Central laboratories
• 6.3 Primary clinics
• 6.4 Hospitals
• 6.5 Other end use

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 India
  • 7.4.3 Japan
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 Agilent Technologies
• 8.3 Beckman Coulter
• 8.4 Becton, Dickinson and Company
• 8.5 bioMerieux
• 8.6 Bio-Rad Laboratories
• 8.7 F. Hoffmann-La Roche
• 8.8 Grifols
• 8.9 Hologic
• 8.10 Illumina
• 8.11 PerkinElmer
• 8.12 QIAGEN
• 8.13 QuidelOrtho
• 8.14 Siemens Healthineers
• 8.15 Thermo Fisher Scientific